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Abstract
Background: In critically ill children, omitting early use of parenteral nutrition (late-PN versus early-PN) reduced
infections, accelerated weaning from mechanical ventilation, and shortened PICU stay. We hypothesized that
fasting-induced ketogenesis mediates these benefits.
Methods: In a secondary analysis of the PEPaNIC RCT (N = 1440), the impact of late-PN versus early-PN on plasma
3-hydroxybutyrate (3HB), and on blood glucose, plasma insulin, and glucagon as key ketogenesis regulators, was
determined for 96 matched patients staying ≥ 5 days in PICU, and the day of maximal 3HB-effect, if any, was
identified. Subsequently, in the total study population, plasma 3HB and late-PN-affected ketogenesis regulators
were measured on that average day of maximal 3HB effect. Multivariable Cox proportional hazard and logistic
regression analyses were performed adjusting for randomization and baseline risk factors. Whether any potential
mediator role for 3HB was direct or indirect was assessed by further adjusting for ketogenesis regulators.
Results: In the matched cohort (n = 96), late-PN versus early-PN increased plasma 3HB throughout PICU days 1–5
(P < 0.0001), maximally on PICU day 2. Also, blood glucose (P < 0.001) and plasma insulin (P < 0.0001), but not
glucagon, were affected. In the total cohort (n = 1142 with available plasma), late-PN increased plasma 3HB on PICU
day 2 (day 1 for shorter stayers) from (median [IQR]) 0.04 [0.04–0.04] mmol/L to 0.75 [0.04–2.03] mmol/L (P <
0.0001). The 3HB effect of late-PN statistically explained its impact on weaning from mechanical ventilation (P =
0.0002) and on time to live PICU discharge (P = 0.004). Further adjustment for regulators of ketogenesis did not alter
these findings.
Conclusion: Withholding early-PN in critically ill children significantly increased plasma 3HB, a direct effect that
statistically mediated an important part of its outcome benefit.
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Introduction
Critically ill patients treated in the pediatric intensive
care unit (PICU) often develop a pronounced macronu-
trient deficit because of the inability to feed orally and
because nutrition administered via nasogastric tubes is
poorly tolerated. The degree of the accumulated macro-
nutrient deficit has been associated with poor outcome
and delayed recovery [1, 2]. However, this association is
confounded by illness severity, given that the sicker pa-
tients are the ones to poorly tolerate enteral feeding.
Furthermore, recent randomized controlled trials (RCTs)
with variable design have not shown unequivocal benefit
by early supplementation of insufficient or failing enteral
nutrition, whereby some RCTs even indicated potential
harm [3–7]. Indeed, the Early versus Late Parenteral
Nutrition in Critically Ill Adults (EPaNIC) and Paediatric
Early versus Late Parenteral Nutrition In Critical Illness
(PEPaNIC) RCTs have shown that withholding paren-
teral nutrition until beyond the first week in intensive
care (late-PN) was clinically superior to early parenteral
nutrition supplementing insufficient enteral nutrition
(early-PN) [4, 5]. As compared with early-PN, late-PN
shortened dependency on intensive medical care in both
RCTs, with a shorter duration of mechanical ventilatory
support, fewer newly acquired infections, and a shorter
intensive care and hospital stay [4, 5]. In critically ill
adults, late-PN also was found to lower the incidence of
weakness [8]. Nevertheless, the optimal timing of initiat-
ing PN remains unclear.
One potential mediator of these clinical benefits
brought about by accepting a macronutrient deficit early
during critical illness is induction of a ketogenic fasting
response. In healthy individuals, a sustained macronutri-
ent deficit induces a fasting response with activated
lipolysis and increased ketogenesis, together resulting in
increased formation of the ketone bodies 3-
hydroxybutyrate (3HB) and acetoacetate [9]. Apart from
being a vital, energy-efficient alternative fuel for the
brain, heart, and skeletal muscle in times of fasting, ke-
tone bodies also play an important signaling role. Ketone
bodies enhance autophagy-driven cellular housekeeping
and activate muscle regeneration [10, 11], pathways that
have been shown to be hampered or insufficiently acti-
vated during critical illness [12, 13]. In addition, ketone
bodies have anti-inflammatory properties [14]. Ketone
bodies or ketogenic diets have shown to increase endur-
ance in healthy athletes [15] and to induce beneficial ef-
fects in animal models of brain injury [16]. Moreover, in
a mouse model of sepsis, a ketogenic PN formula and
supplementation of PN with 3HB have shown to protect
against the development of muscle weakness [17].
It remains unknown, however, whether critically ill pa-
tients can increase ketogenesis in response to the illness-
associated macronutrient deficit, and whether such
ketogenic response—if present—is beneficial for recov-
ery. In healthy subjects, fasting-induced ketogenesis is
mediated by low circulating levels of insulin and glucose
as well as high levels of glucagon, cortisol, and catechol-
amines [18–20]. In critical illness, however, although
plasma glucagon, cortisol, and catecholamines are ele-
vated, concomitant hyperinsulinemia and hyperglycemia
may suppress ketogenesis [20, 21]. In line with this,
available data, though scarce, suggested suppressed keto-
genesis during critical illness [22–25]. Withholding
early-PN has shown to reduce the degree of hypergly-
cemia, to lower the insulin requirements to prevent
hyperglycemia [4, 5], and to lower the insulin/glucagon
ratio [26].
We hypothesized that withholding early-PN enhances
ketogenesis during critical illness and that such fasting-
induced ketogenesis could be a mediator of the previ-
ously demonstrated recovery-enhancing effect of omit-
ting PN early during critical illness [5]. We tested these
hypotheses in a secondary analysis of the PEPaNIC RCT.
Methods
Patients and study design
This is a secondary analysis of the multicenter (Leuven,
BE, Rotterdam, NL, Edmonton, CA) PEPaNIC random-
ized controlled trial (ClinicalTrials.gov NCT01536275,
n = 1440). Written informed consent was obtained from
the parents or legal guardians. The institutional or na-
tional ethical review boards of the participating centers
approved the study protocol which was performed in ac-
cordance with the 1964 Declaration of Helsinki and later
amendments. The detailed study protocol and primary
results of the PEPaNIC study have been published [5,
27]. The study investigated the effect of omitting the use
of PN to beyond the first week in the PICU (late-PN) as
compared with the use of PN to complete insufficient or
failing enteral nutrition from PICU admission onwards
(early-PN). In both randomization groups, enteral nutri-
tion was initiated as soon as possible, and gradually ad-
vanced up to target as tolerated. Beyond the first week,
both groups received supplemental PN as long as
patients were not fully enterally fed. To match the fluid
intake of patients in the early-PN group, patients in the
late-PN group received an isovolemic intravenous mix-
ture of dextrose 5% and normal saline. To prevent
refeeding syndrome, patients in both groups received
intravenous trace elements, minerals, and vitamins,
started on day 2 and continued until full enteral nutri-
tion. Hyperglycemia was prevented with the use of intra-
venous insulin infusion, with center-specific target
ranges [5, 27].
First, to evaluate whether and in which timeframe
late-PN versus early-PN would affect ketogenesis, a time
course analysis was planned in a matched subset of
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patients (Fig. 1). All patients who stayed in the PICU for
at least 5 days and for whom daily stored plasma samples
were available from admission until day 5 in PICU were
selected in the Leuven, Rotterdam, and Edmonton co-
horts. For Edmonton, this resulted in 0 children; for
Rotterdam, this selection resulted in a cohort of 45 chil-
dren; for Leuven, this selection resulted in a cohort of
199 children. To avoid confounding of the center-
specific insulin treatment strategies which could have af-
fected plasma 3HB concentrations differently, the
Leuven cohort was further reduced to a similar size as
the Rotterdam cohort (n = 51) by propensity score
matching. The resulting total cohort consisted of 96 pa-
tients (47 early-PN and 49 late-PN patients) matched for
demographics (age, gender, weight) and baseline type
and severity of illness (nutritional risk level according to
STRONGkids category, probability of death score evalu-
ated by PIM2 score, emergency versus planned admis-
sion, diagnostic group, need of hemodynamic assist
device on admission, presence of infection on admission)
(Table 1). In this set, the impact of late-PN versus early-
PN on daily plasma concentrations of 3HB as well as on
blood glucose, plasma insulin, and glucagon concentra-
tions, potential regulators of ketogenesis, was deter-
mined. The time point of the maximal 3HB effect, if any,
was then identified. Second (Fig. 1), for all patients in
the PEPaNIC trial who had a plasma sample available
for that average day of maximal effect (or last day in
PICU for patients who were discharged from or died in
the PICU before that day), plasma 3HB concentrations
and also blood glucose, plasma insulin, and glucagon
concentrations—if found to be affected in the above time
Fig. 1 Rationale and stepwise design of the study. In step 1, a time course analysis to investigate any impact of late-PN versus early-PN on daily
plasma concentrations of 3HB. Therefore, all patients with a PICU stay of at least 5 days and plasma samples available from admission until day 5
in the PICU were selected and matched for center, demographics, and type and severity of illness. In the resulting matched cohort of 96 children,
daily plasma 3HB, insulin, glucagon, and glucose concentrations were determined and the time point of “maximal 3HB effect” was identified. In
step 2, in the total study population, the concentration of plasma 3HB and in step 1 affected ketogenic regulators were determined on the
average time point of “maximal 3HB effect” identified in step 1. For patients with a shorter PICU stay, the sample on the last day in PICU was
used as surrogate (1142 patients with available plasma, of which 580 randomized to late-PN and 562 randomized to early-PN). In step 3, a
multivariable statistical analysis was performed to assess whether any impact of late-PN as compared with early-PN on 3HB could explain its
beneficial effects on outcome. “a” represents the effect of the intervention (late-PN versus early-PN) on the outcome of interest (time to live
weaning from mechanical ventilatory support, time to live PICU discharge, and acquisition of new infection), “b” represents the effect of the
intervention (late-PN versus early-PN) on the hypothesized mediator—plasma 3HB concentration, and “c” represents the association of the
potential mediator with the outcome of interest (time to live weaning from mechanical ventilatory support, time to live PICU discharge, and
acquisition of new infection)
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course study—were determined and compared for the
late-PN and early-PN groups. Third (Fig. 1), a multivari-
ate mediation analysis [28–30] was then performed on
the total study cohort to assess whether any impact of
late-PN as compared with early-PN on 3HB could ex-
plain its beneficial effects on outcome, adjusted for
demographics, baseline risk factors, and type and sever-
ity of illness. If so, it was further assessed whether such
a mediation role for 3HB was direct or indirect via an ef-
fect of late-PN on key regulators of ketogenesis, again
adjusted for demographics, baseline risk factors, and
type and severity of illness.
Plasma analyses
Plasma insulin and plasma glucagon concentrations were
measured with commercial ELISAs (Invitrogen Ltd.,
Waltham, MA, USA, and Mercodia, Uppsala, Sweden),
and blood glucose concentrations with the use of the
ABL Radiometer. Plasma 3HB was quantified with a la-
boratory assay based upon the oxidation of 3HB to
Table 1 Baseline characteristics of matched patients in the time course study
Baseline characteristics Early-PN (n = 47) Late-PN (n = 49) P value
Age (years)—median [IQR]2 4.3 [0.2–8.4] 3.5 [0.4–11.6] 0.4
Age < 1 year—no. (%) 16 (34.0) 18 (36.7) 0.8
Male sex—no. (%) 28 (59.5) 34 (69.3) 0.3
Weight (kg)—median [IQR]2 15.0 [4.7–24.0] 14.0 [5.6–34.0] 0.5
STRONGkids risk level—no. (%)1 1
Medium (1–3) 44 (93.6) 46 (93.8)
High (4, 5) 3 (6.3) 3 (6.1)
PIM2 calc. risk of death (%)—median [IQR]2 0.20 [0.08–0.37] 0.16 [0.06–0.33] 0.6
Emergency admission—no. (%) 16 (34.0) 15 (30.6) 0.8
Center—no. (%)
Leuven 25 (53.1) 26 (53.0)
Rotterdam 22 (46.8) 23 (46.9)
Edmonton 0 (0) 0 (0)
Diagnostic group—no. (%)
Surgical
Abdominal 0 (0) 2 (4.08)
Burns 0 (0) 0 (0)
Cardiac 16 (34.0) 18 (36.7)
Neurosurgery-traumatic brain injury 8 (17.0) 7 (14.2)
Thoracic 0 (0) 0 (0)
Transplantation 4 (8.5) 2 (4.1)
Orthopedic surgery-trauma 3 (6.3) 0 (0)
Others 1 (2.1) 0 (0)
Medical
Cardiac 2 (4.2) 5 (10.2)
Gastrointestinal-hepatic 0 (0) 0 (0)
Oncologic-hematologic 0 (0) 1 (2.0)
Neurologic 1 (2.1) 3 (6.1)
Respiratory 5 (10.6) 7 (14.2)
Others 7 (14.8) 4 (8.1)
Condition on admission—no. (%)
Need for hemodynamic assist device 1 (0.02) 1 (0.02) 0.2
Presence of infection 26 (55.3) 24 (48.9) 0.5
1Scores on the Screening Tool for Risk on Nutritional Status and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a
score of 1 to 3 indicating medium risk, and a score of 4 to 5 indicating high risk. 2Pediatric index of mortality 2 (PIM2) is a severity scoring system for predicting
outcome of patients admitted to pediatric intensive care units
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acetoacetate by the enzyme 3-hydroxybutyrate dehydro-
genase and the concomitant reduction of cofactor
NAD+ to NADH [31]. Plasma samples were added to a
reaction mixture containing EDTA (2 mM), sodium oxa-
mate (13 mM), NAD (3 mM), and 3-hydroxybutyrate
dehydrogenase (1.5 U/ml, 3HBDB-RO Sigma-Aldrich) in
Bis-Tris-Propane Buffer (50 mM, pH 9.5). The change in
NADH fluorescence, compared to sample with reaction
mixture without dehydrogenase, measured in a black 96-
well plate with transparent bottom after 15 min at 30 °C,
is directly related to the 3HB, with a detection limit of
0.04 mmol/l (excitation 340 nm, emission 445 nm, Tecan
Infinite 200, Tecan Ltd., Männedorf, Switzerland).
Statistical analyses
Data are presented as frequencies and percentages or
medians with interquartile range. Fisher’s exact test and
Kruskal-Wallis test were used to analyze univariable dif-
ferences between patient groups, as appropriate. Multi-
variable Cox proportional hazard analysis was used to
assess (first) whether randomization to late-PN or early-
PN independently associated with the time to live wean-
ing from mechanical ventilatory support and the time to
live discharge from the PICU, and (second) whether
3HB concentrations on the average day of maximal ef-
fect (or last day in PICU for patients with a shorter
PICU stay) independently associated with these out-
comes when added to this model. Likewise, multivariable
logistic regression analysis was used to study whether
randomization and 3HB concentrations independently
associated with the incidence of a new infection in the
PICU. Multivariable Cox proportional hazard and logis-
tic regression analyses were adjusted for baseline risk
factors (age, weight, gender, emergency versus elective
admission, diagnostic group, PIM2 score, STRONGkids
category, need of hemodynamic assist device on admis-
sion, presence of infection on admission), with censoring
performed at 90 days or death. In those cases where add-
ing the plasma 3HB concentration to the multivariable
models showed that they were independently associated
with the outcome of interest, hereby replacing the effect
of the randomization to late-PN versus early-PN on the
outcome, the 3HB effect was considered a statistical me-
diator of the late-PN outcome effect. To assess whether
any potential mediator role for 3HB was direct or indir-
ect via an effect of late-PN on key regulators of ketogen-
esis (plasma insulin, glucagon, and/or blood glucose
concentrations) [18], sensitivity analyses were performed
in which models were further adjusted for those regula-
tors that were found to be affected by late-PN. In
addition, multivariable logistic regression analysis was
used to investigate the independent association between
plasma 3HB concentration and PICU mortality. All ana-
lyses were performed with the use of JMP software,
version pro 14 (SAS Institute, NC, USA). Statistical sig-
nificance was set at a P value of 0.0083 for the time
course analysis (Bonferroni correction for multiple test-
ing) and at 0.05 for other comparisons.
Results
Effect of late-PN versus early-PN on daily plasma
concentrations of 3HB and identification of the time point
of the maximal effect, if any
The matched cohort of patients with plasma samples
available for each of the first 5 PICU days comprised
47 early-PN and 49 late-PN patients (Table 1, Fig. 1).
Due to practical reasons, there was a slight time delay
between initiation of the randomized intervention at
PICU admission and the moment of drawing the ad-
mission sample, ranging from 0 to 7 h (median [IQR]
36 [18–74] min).
Compliant with the study protocol, the daily total cal-
oric intake was lower in late-PN patients than in early-
PN patients throughout the 5 first days in PICU (all P <
0.0001) (Fig. 2a). Similar as in the total study population,
late-PN patients developed an important macronutrient
deficit over the first week in the PICU as compared to
early-PN patients. From day 1 to day 5, plasma insulin
concentrations were lower in late-PN patients than in
early-PN patients (all P < 0.0001) (Fig. 2b). Plasma gluca-
gon concentrations were not different (Fig. 2c). From ad-
mission until day 2, blood glucose concentrations were
lower in the late-PN group (all P ≤ 0.004) (Fig. 1d).
Throughout the 5 days, plasma 3HB concentrations were
higher in late-PN patients than in early-PN patients (P =
0.02 for admission and P < 0.0001 for days 1 to 5), with
the largest difference observed for day 2 (Fig. 2e).
Effect of late-PN versus early-PN on plasma 3HB
concentration on the “maximal effect day” in the total
study cohort
Given that day 2 in PICU was identified as the day upon
which the difference in median 3HB between late-PN
patients and early-PN patients was the largest, plasma
3HB was quantified for all study patients with an avail-
able plasma sample on day 2 (n = 822). For patients with
a PICU stay of less than 2 days, the plasma samples of
day 1 were used (n = 320) as surrogate.
For these 1142 patients, demographics, admission
diagnosis, and baseline severity of illness were compar-
able between the 580 late-PN patients and 562 early-PN
patients (Table 2). Cumulative caloric intake until blood
sampling was lower in late-PN patients than in early-PN
patients (P < 0.0001) (Fig. 3a). As in the time course
study, plasma insulin and blood glucose concentrations
were also lower in late-PN than in early-PN patients
(both P < 0.0001) (Fig. 3b, c). Given that the time course
study did not show an effect of late-PN on plasma
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glucagon, this analyte was not measured for the entire
study cohort. Plasma 3HB concentrations were
significantly higher in late-PN than in early-PN patients
((median [IQR]) 0.04 [0.04–0.04] mmol/L versus
0.75[0.04–2.03] mmol/L; P < 0.0001) (Fig. 3d).
Multivariable outcome analysis to assess whether the
impact of late-PN versus early-PN on 3HB could explain
its beneficial effects on outcome
In the total study cohort (n = 1142), and adjusted for
baseline risk factors, randomization to late-PN as com-
pared with early-PN was independently associated with a
higher likelihood of an earlier live weaning from mech-
anical ventilation and earlier live discharge from the
PICU and with less newly acquired infections in the
PICU (Table 3, panel 1). Adding the plasma 3HB con-
centrations measured on day 2 (or day 1 for shorter
stayers) to the multivariable models revealed that a
higher plasma 3HB concentration was independently as-
sociated with a higher likelihood of earlier live weaning
from mechanical ventilatory support (P = 0.0002) and of
earlier live PICU discharge (P = 0.004), hereby replacing
the effect of randomization to late-PN versus early-PN
(Table 3, panel 2), thus suggesting a mediator role for
the 3HB effect of late-PN on these two outcomes. Fur-
ther adjustment for the affected key regulators of keto-
genesis (plasma insulin concentration, blood glucose
concentration) did not alter these results (Table 3, panel
3). The effect of late-PN versus early-PN on plasma 3HB
did not explain its impact on infections (Table 3, panels
2 and 3).
Plasma 3HB concentrations were not independently
associated with PICU mortality (Additional Table 1).
Discussion
This secondary analysis of the PEPaNIC RCT revealed
that late-PN, as compared with early-PN, associated with
increased plasma 3HB concentrations from the first
hours in PICU onward, sustained for at least 5 days, and
with a maximal rise observed on PICU day 2. Also, levels
of the key regulators of ketogenesis, blood glucose and
insulin, were lowered whereas glucagonemia was un-
affected. Statistical mediation analyses suggested that the
rise in plasma 3HB concentrations with late-PN, as com-
pared with early-PN, explained its accelerating impact
on live weaning from mechanical ventilatory support
and on live discharge from the PICU, but not its pre-
ventive effect on newly acquired infections. This role of
increased 3HB as a potential mediator of 2 major
Fig. 2 Total caloric intake, plasma insulin, plasma glucagon, blood
glucose, and plasma 3HB concentrations during the first 5 days in
PICU in a matched cohort of early-PN and late-PN patients. Data are
shown as median and IQR
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outcome benefits of late-PN was a direct one, as it was
independent of the observed changes in the key regula-
tors of ketogenesis.
With late-PN, and thus with accepting an important
macronutrient deficit during the first week in the PICU,
plasma 3HB concentrations were found to rise up to the
millimolar range. This high level of plasma 3HB in re-
sponse to late-PN was striking given that earlier studies
had suggested impaired ketogenesis during critical
illness in adults [22–25]. Hyperinsulinemia and
hyperglycemia are powerful suppressors of ketogenesis
and hallmarks of critical illness [20, 21]. Glucagon, corti-
sol, and catecholamines are hormones known to en-
hance ketogenesis in healthy subjects, and levels of these
stress hormones are elevated during critical illness [18,
32]. However, as shown previously for cortisol [33], and
now also for glucagon, not using early-PN did not affect
the plasma levels of these ketogenic hormones in critic-
ally ill children. Also, the use of corticosteroids and of
catecholamines was unaffected by late-PN, as shown
Table 2 Baseline characteristics of patients in the total study cohort
Baseline characteristics Early-PN (n = 580) Late-PN (n = 562) P value
Age (years)—median [IQR]2 1.8 [0.3–6.7] 1.9 [0.3–8.4] 0.4
Age < 1 year—no. (%) 238 (41.0) 228 (40.5) 0.9
Male gender—no. (%) 323 (55.6) 324 (57.6) 0.5
Weight (kg)—median [IQR]2 11.1 [5.3–21.0] 12.0 [5.1–25.0] 0.3
STRONGkids risk level—no. (%)1 0.8
Medium (1–3) 530 (91.3) 511 (90.9)
High (4, 5) 50 (8.6) 51 (9.0)
PIM2 calc. risk of death (%)—median [IQR]2 0.06 [0.02–0.21] 0.06 [0.02–0.017] 0.5
Emergency admission—no. (%) 272 (46.9) 271 (48.2) 0.6
Center—no. (%)
Leuven 371 (63.9) 372 (66.1)
Rotterdam 173 (29.8) 161 (28.6)
Edmonton 36 (6.2) 29 (5.1)
Diagnostic group—no. (%)
Surgical
Abdominal 25 (4.3) 27 (4.8)
Burns 3 (0.5) 5 (0.8)
Cardiac 266 (45.8) 255 (45.3)
Neurosurgery-traumatic brain injury 59 (10.1) 46 (8.1)
Thoracic 24 (4.1) 20 (3.5)
Transplantation 7 (1.2) 15 (2.6)
Orthopedic surgery-trauma 27 (4.6) 26 (4.6)
Others 11 (1.9) 19 (3.3)
Medical
Cardiac 22 (3.7) 22 (3.9)
Gastrointestinal-hepatic 2 (0.3) 3 (0.5)
Oncologic-hematologic 4 (0.6) 7 (1.2)
Neurologic 41 (7.0) 36 (6.4)
Respiratory 54 (9.3) 52 (9.2)
Others 35 (6.0) 29 (5.1)
Condition on admission—no. (%)
Need for hemodynamic assist device 17 (0.0) 23 (0.0) 0.2
Presence of infection 212 (36.5) 193 (34.3) 0.4
1Scores on the Screening Tool for Risk on Nutritional Status and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a
score of 1 to 3 indicating medium risk, and a score of 4 to 5 indicating high risk. 2Pediatric index of mortality 2 (PIM2) is a severity scoring system for predicting
outcome of patients admitted to pediatric intensive care units
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previously [5, 33]. In contrast, not using early-PN low-
ered blood glucose and plasma insulin concentrations in
the current study, in line with the earlier finding of a
lowered insulin requirement to prevent hyperglycemia
[4, 5]. Together, this suggests that late-PN, as compared
with early-PN, increased plasma 3HB concentrations
throughout the first 5 days in the PICU by reducing sup-
pressors of ketogenesis rather than by enhancing keto-
genesis activators.
With late-PN, the highest rise in plasma 3HB concen-
trations was observed on day 2 in the PICU with con-
centrations declining somewhat thereafter, though
staying elevated throughout the first 5 days in the PICU.
This decline corresponds with the increase in the
amount of enteral nutrition from day 2 onwards, al-
though that amount was still small. It is well known that
ketogenesis is very sensitive to suppression by macronu-
trient intake [9]. Also, given that the blood glucose levels
were no longer different after PICU day 2, and hypergly-
cemia is a known suppressor of ketogenesis [22], the
blood glucose effect may have contributed to the peak
rise in plasma 3HB on that day. Remarkably, although
children were not fully fasted during these first PICU
days, receiving minimal doses of IV glucose and re-
ceiving blood glucose control with insulin infusion,
the plasma ketone concentrations in the late-PN
group rose quite high, up to the millimolar range.
This may have to do with the young age of the critic-
ally ill patients of this study, as the ketogenic fasting
response in children is known to be more pro-
nounced than in adults [9, 22–25].
The statistical mediation analyses suggested that the
rise in plasma 3HB concentrations with late-PN, as com-
pared with early-PN, explained its accelerating impact
on live weaning from mechanical ventilatory support
and on live discharge from the PICU, but not its pre-
ventive effect on newly acquired infections. The mech-
anism by which 3HB may enhance recovery from critical
illness cannot be identified in the current study. One
possibility is that 3HB, during critical illness, similarly as
during prolonged fasting in healthy subjects, serves as a
vital or super fuel for the brain, heart, and skeletal
muscle [9]. In healthy athletes, ingestion of 3HB esters
has shown to increase endurance [15]. Also, in a mouse
model of sepsis, a ketogenic PN formula and supplemen-
tation of PN with 3HB have shown to protect against
Fig. 3 Total caloric intake, plasma insulin, blood glucose, and plasma
3HB concentrations on day 1/2 in the total cohort of early-PN and
late-PN patients. Plasma concentrations of 3-HB and insulin were
determined on day 2 in PICU or on day 1 for patients with a shorter
PICU stay. Boxes show median and IQR, whiskers 10th and
90th percentile
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Table 3 A 3-step approach to investigate a potential mediation role of the effect on 3HB for the outcome benefits of late-PN
Likelihood of live weaning
from mechanical ventilatory
support
Likelihood of live discharge
from the PICU
Acquisition of a new infection
in the PICU
A. Impact of randomization (n = 1142) Risk ratio (95% CI) P value Risk ratio (95% CI) P value Odds ratio (95% CI) P value
Randomization to late-PN (n = 562)
vs. early-PN (n = 580)
1.14 (1.01–1.29) 0.02 1.19 (1.06–1.35) 0.003 0.49 (0.34–0.70) < 0.0001
Demographics
Age per year added 1.02 (0.98–1.05) 0.18 1.02 (0.99–1.06) 0.11 1.02 (0.93–1.13) 0.59
Weight per kg added 0.99 (0.98–1.00) 0.65 0.99 (0.98–1.00) 0.34 0.99 (0.96–1.02) 0.72
Male gender 0.98 (0.85–1.11) 0.85 0.94 (0.83–1.07) 0.39 1.11 (0.78–1.58) 0.52
Characteristics of type and severity of illness
Emergency vs. planned admission 0.74 (0.61–0.90) 0.003 0.77 (0.63–0.93) 0.008 1.74 (1.03–2.92) 0.03
Diagnostic group 0.22 0.40 0.06
PIM2 score per point added 0.70 (0.66–0.74) < 0.0001 0.72 (0.68–0.76) < 0.0001 1.41 (1.25–1.60) < 0.0001
High vs. medium risk of malnutrition
(STRONGkids risk level 4–5 vs. 1–3)
0.86 (0.68–1.06) 0.17 0.83 (0.67–1.03) 0.1 1.15 (0.65–2.02) 0.62
Presence of infection on admission 0.72 (0.61–0.84) < 0.0001 0.71 (0.61–0.84) < 0.0001 0.52 (0.32–0.83) 0.005
Need for hemodynamic assist device on admission 0.51 (0.34–0.76) 0.001 0.48 (0.32–0.73) 0.0005 1.71 (0.80–3.64) 0.16
B. Mediation role for plasma 3HB (n = 1142) Risk ratio (95% CI) P value Risk ratio (95% CI) P value Odds ratio (95% CI) P value
Plasma 3HB on day 2 (per mmol/l)1 1.12 (1.05–1.20) 0.0002 1.10 (1.03–1.17) 0.004 0.85 (0.68–1.06) 0.14
Randomization to late-PN (n = 562)
vs. early-PN (n = 580)
1.01 (0.88–1.16) 0.79 1.08 (0.94–1.24) 0.26 0.56 (0.38–0.84) 0.004
Demographics
Age per year added 1.02 (0.99–1.06) 0.11 1.03 (0.99–1.06) 0.06 1.02 (0.92–1.12) 0.64
Weight per kg added 0.99 (0.98–1.00) 0.55 0.99 (0.98–1.00) 0.28 0.99 (0.96–1.02) 0.72
Male gender 0.99 (0.88–1.12) 0.95 0.95 (0.84–1.07) 0.44 1.11 (0.78–1.57) 0.55
Characteristics of type and severity of illness
Emergency vs. planned admission 0.77 (0.63–0.94) 0.01 0.79 (0.65–0.96) 0.02 1.65 (0.98–2.79) 0.05
Diagnostic group 0.27 0.32 0.07
PIM2 score per point added 0.70 (0.66–0.74) < 0.0001 0.72 (0.68–0.76) < 0.0001 1.41 (1.24–1.60) < 0.0001
High vs. medium risk of malnutrition 0.85 (0.68–1.05) 0.14 0.83 (0.67–1.03) 0.09 1.16 (0.66–2.05) 0.59
Presence of infection on admission 0.72 (0.61–0.85) < 0.0001 0.72 (0.61–0.84) < 0.0001 0.51 (0.32–0.82) 0.004
Need for hemodynamic assist device on admission 0.50 (0.33–0.76) 0.001 0.48 (0.32–0.73) 0.0001 1.66 (0.78–3.55) 0.19
C. Sensitivity analysis (direct/indirect 3HB effect)
(n = 1142)
Risk ratio (95% CI) P value Risk ratio (95% CI) P value Odds ratio (95% CI) P value
Plasma 3HB on day 2 (per mmol/l)1 1.12 (1.05–1.19) 0.0005 1.09 (1.02–1.17) 0.007 0.80 (0.63–1.02) 0.06
Randomization to late-PN (n = 562)
vs. early-PN (n = 580)
0.97 (0.83–1.12) 0.70 1.04 (0.89–1.21) 0.60 0.62 (0.40–0.94) 0.02
Demographics
Age per year added 1.03 (0.99–1.06) 0.08 1.03 (0.99–1.06) 0.06 1.03 (0.93–1.14) 0.50
Weight per kg added 0.99 (0.98–1.00) 0.67 0.99 (0.98–1.00) 0.36 0.99 (0.96–1.02) 0.54
Male gender 0.97 (0.86–1.11) 0.74 0.94 (0.83–1.06) 0.34 1.19 (0.83–1.72) 0.33
Characteristics of type and severity of illness
Emergency vs. planned admission 0.72 (0.59–0.89) 0.002 0.76 (0.62–0.93) 0.01 1.62 (0.94–2.79) 0.07
Diagnostic group 0.28 0.42 0.03
PIM2 score per point added 0.69 (0.65–0.73) < 0.0001 0.72 (0.68–0.75) < 0.0001 1.45 (1.27–1.65) < 0.0001
High vs. medium risk of malnutrition 0.84 (0.67–1.04) 0.12 0.82 (0.65–1.02) 0.07 1.15 (0.64–2.06) 0.63
Presence of infection on admission 0.72 (0.61–0.85) 0.0001 0.72 (0.62–0.85) 0.0001 0.49 (0.30–0.81) 0.004
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the development of muscle weakness [17]. Alternatively,
3HB may act through enhanced autophagy-driven cellu-
lar housekeeping [10], a pathway that was previously
shown to be activated by late-PN in critically ill adults
[13]. Another possibility is a 3HB-driven activation of
muscle regeneration, as was shown earlier in a mouse
model of sepsis [11]. Finally, although 3HB may also
have anti-inflammatory effects [14], such a mechanism
appears less likely, given that late-PN has shown to in-
crease plasma C-reactive protein concentrations, consid-
ered to be a marker of inflammation [4, 5]. The finding
that the rise in 3HB with late-PN did not explain its pre-
ventive impact on new infections also suggests that an
immune modulating effect of 3HB does not seem to be
involved.
Adjustment for key suppressors of ketogenesis, blood
glucose and plasma insulin [18, 20, 22], that were low-
ered by late-PN, did not affect the statistical mediating
role of the rise in plasma 3HB concentrations with late-
PN on outcome. This suggests that the effect of the rise
in 3HB on accelerated recovery was a direct one, rather
than that it merely mirrored the impact of lowered insu-
lin or blood glucose. This was further supported by the
finding that plasma insulin concentrations were not in-
dependently associated with the late-PN-affected out-
comes in the multivariable models. Interestingly, a lower
blood glucose concentration was independently associ-
ated with a higher likelihood of earlier live weaning from
mechanical ventilator support. Targeting normal fasting
levels of blood glucose with insulin in adults has previ-
ously shown to protect against critical illness-induced
polyneuropathy/myopathy, an important cause of limb
and respiratory muscle weakness, and a complication
that prolongs the need for mechanical ventilation [34,
35]. However, as compared with the large impact on
blood glucose in those studies, the difference in blood
glucose between late-PN and early-PN that was observed
here was small. Altogether, our data open perspectives
for studies investigating the impact of exogenous ketone
supplementation or ketogenic diets on outcome of
critically ill patients. Possibly, such strategies could allow
effective and safe initiation of artificial feeding while
avoiding prolonged fasting intervals, a hypothesis that
requires further study. Evidently, future studies should
also investigate potential side effects of such feeding
strategies, such as gastrointestinal tolerance and, for ke-
togenic diets, metabolic acidosis.
One strength of this study is the design as a secondary
analysis of a large RCT, with prospectively planned col-
lection of plasma samples on a daily basis. This allowed
to perform repeated measurements and to identify the
time point of the maximal 3HB effect. This study has
also limitations. First, not all patients of the original co-
hort had a sample available for the day of the maximal
3HB effect. However, samples were available for 1142 of
the 1440 patients and the late-PN and early-PN groups
were still comparable for demographics, admission diag-
nosis, and baseline severity of illness. Also, the outcome
benefits of late-PN versus early-PN were present in the
cohort of 1142 patients and comparable to those in the
1440 patient cohort. A second limitation is that the me-
diation analyses were performed with plasma 3HB con-
centrations quantified on a single time point, namely the
day of the maximal 3HB effect. It thus remains unclear
whether the observed positive effect of plasma 3HB con-
centrations on outcome is related to its peak effect or to
the duration of enhanced ketogenesis during critical ill-
ness. Third, in the sensitivity mediation analyses, in
which it was investigated whether the impact of late-PN
versus early-PN on plasma insulin and blood glucose
played a role, it cannot be excluded that other, yet
unknown, factors were involved. Finally, this study was
performed in a pediatric ICU population. Whether these
findings can be extrapolated to adult ICU patients re-
quires further investigation.
Conclusion
Withholding PN during the first week in the PICU,
whereby suppressors of ketogenesis were reduced, rap-
idly increased plasma 3HB concentrations up to the
Table 3 A 3-step approach to investigate a potential mediation role of the effect on 3HB for the outcome benefits of late-PN
(Continued)
Likelihood of live weaning
from mechanical ventilatory
support
Likelihood of live discharge
from the PICU
Acquisition of a new infection
in the PICU
Need for hemodynamic assist device on
admission
0.51 (0.34–0.78) 0.002 0.48 (0.32–0.74) 0.0008 1.44 (0.66–3.13) 0.36
Late-PN-affected regulators of ketogenesis
Plasma insulin at time of 3HB assessment
(per μIU/l)
1.00 (0.99–1.00) 0.93 0.99 (0.99–1.00) 0.52 0.80 (0.63–1.02) 0.76
Blood glucose at time of 3HB assessment
(per mg/dl)
0.99 (0.99–0.99) 0.02 0.99 (0.99–1.00) 0.46 0.99 (0.99–1.00) 0.49
1Plasma 3HB was quantified for all study patients with an available plasma sample on day 2 (n = 822) or day 1 (n = 320) for patients with a shorter PICU stay
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millimolar range, an effect that was sustained for at least
5 days. This 3HB effect of withholding PN was found to
be a direct statistical mediator of an important part of
its beneficial impact on recovery. These findings open
perspectives for the further investigation of ketone sup-
plementation and of ketogenic diets to improve outcome
of critically ill patients.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13054-020-03256-z.
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